Shares of AtriCure (NASDAQ:ATRC) have been given a consensus recommendation of “Buy” by the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $25.00.
ATRC has been the subject of several recent research reports. Needham & Company LLC lifted their target price on shares of AtriCure from $23.00 to $26.00 and gave the company a “buy” rating in a report on Friday, April 27th. ValuEngine upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a report on Saturday, May 12th. Canaccord Genuity lifted their target price on shares of AtriCure from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Stifel Nicolaus raised their price target on shares of AtriCure from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, April 27th. Finally, BidaskClub raised shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd.
AtriCure opened at $24.08 on Monday, MarketBeat Ratings reports. AtriCure has a 52-week low of $14.88 and a 52-week high of $25.18. The company has a market cap of $843.76 million, a PE ratio of -29.01 and a beta of 0.25. The company has a quick ratio of 2.31, a current ratio of 3.15 and a debt-to-equity ratio of 0.34.
AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, April 26th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.04). AtriCure had a negative net margin of 14.88% and a negative return on equity of 16.92%. The business had revenue of $46.99 million for the quarter, compared to analysts’ expectations of $45.43 million. During the same quarter in the previous year, the business posted ($0.32) earnings per share. AtriCure’s revenue for the quarter was up 13.9% on a year-over-year basis. sell-side analysts predict that AtriCure will post -0.86 EPS for the current year.
In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction that occurred on Tuesday, May 8th. The shares were sold at an average price of $22.82, for a total value of $228,200.00. Following the completion of the sale, the director now owns 29,967 shares of the company’s stock, valued at approximately $683,846.94. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 8.70% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. grew its position in AtriCure by 1.7% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 173,033 shares of the medical device company’s stock worth $3,157,000 after purchasing an additional 2,932 shares during the period. Essex Investment Management Co. LLC boosted its stake in shares of AtriCure by 2.4% during the 4th quarter. Essex Investment Management Co. LLC now owns 145,258 shares of the medical device company’s stock worth $2,650,000 after acquiring an additional 3,460 shares during the last quarter. Capital Fund Management S.A. boosted its stake in shares of AtriCure by 57.3% during the 4th quarter. Capital Fund Management S.A. now owns 15,100 shares of the medical device company’s stock worth $275,000 after acquiring an additional 5,500 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of AtriCure by 105.1% during the 1st quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock worth $292,000 after acquiring an additional 7,281 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in shares of AtriCure during the 1st quarter worth $208,000. 87.56% of the stock is owned by institutional investors and hedge funds.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.